High-Risk Myeloma: Redefining Risk and Evolving Treatment Strategies

The definition of high-risk multiple myeloma is evolving beyond traditional cytogenetic abnormalities to incorporate genomic profiling, measurable residual disease (MRD) assessment, and advanced imaging biomarkers that more accurately predict disease behavior and treatment outcomes. This session will review emerging approaches to risk stratification, including the role of genomic staging systems, dynamic MRD monitoring, and functional imaging in identifying patients at greatest risk for early relapse and treatment resistance. Dr. Paul Richardson will discuss contemporary treatment strategies for high-risk disease, highlighting data from recent clinical trials evaluating CD38-based quadruplet regimens, MRD-adapted approaches, bispecific antibodies, and CAR-T cell therapies. Attendees will gain practical insights into applying modern risk assessment tools and optimizing individualized treatment strategies to improve outcomes in this challenging patient population.